^
    Back
    Association details:
    Biomarker:EZH2 Y641F
    Cancer:Melanoma
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor) +
    JQEZ5 (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Med
    Title:

    An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome

    Excerpt:
    Dabrafenib and JQEZ5 resulted in tumor growth inhibition in both Ezh2+/+ and Ezh2Y641F/+ tumors, with Dabrafenib being the more potent agent. Combinatorial treatment with Dabrafenib and JQEZ5 resulted in additive activity in Ezh2Y641F/+ but not Ezh2+/+ tumors...and is effective in combination with a B-RAF inhibitor in RAF-mutant melanoma.
    DOI:
    10.1038/nm.4092